Caring Ambassadors Hepatitis C Program Newsletter
Legendary heavy-metal DJ Tawn Mastrey—the disease that took her life http://www.citypages.com/2009-04-01/music/legendary-heavy-metal-dj-tawn-mastrey-mdash-the-disease-that-took-her-life/
“Best known locally for her work with heavy-rock station 93X, DJ Tawn Mastrey led the kind of life that is usually reserved for fiction. After hitchhiking to California at the age of 17, she put herself through broadcasting school and landed gigs as a DJ in the Bay Area and then Los Angeles, interviewing rock stars and becoming close friends with people like Slash, Ozzy Osborne, and Sammy Hagar.
Tawn Mastrey, a.k.a. the Leather NunDuring the '80s, Mastrey was credited with popularizing then-unknown bands like Mötley Crüe and Poison, pushing hair bands and heavy rock onto the commercial airwaves. Her Wikipedia page credits her for "breaking" AC/DC and the Police single "Roxanne." Mastrey's radio shows and interviews were soon picked up for national syndication. Dubbed the "Leather Nun," she was renowned by rock lovers everywhere for being a sassy, strong woman in a field traditionally reserved for egomaniacal men.
Throughout her career as a DJ, Mastrey followed a steady upward trajectory. She moved back to her home state of Minnesota and worked as a DJ on the heavy-metal-friendly station 93X during the late '90s, then took a national gig at Sirius Satellite Radio as the host of Hair Nation. But things took a dramatic turn around the time she started working for Sirius. In the early 2000s, Mastrey began to feel sick, as if she had contracted a flu that she just couldn't shake.
"She became ill and she didn't know why," says Mastrey's younger sister Cara, seated at the dining room table in her bohemian south Minneapolis apartment, surrounded by photos of Tawn. "They did all sorts of tests, and finally it came out that she had the hepatitis C virus. She didn't even know what that was." Read more...
Increase in STDs a concern of new health commissioner
“Unprotected sex and intravenous drug use can be blamed for causing 50 percent of the infectious diseases reported in Columbiana County, but one local health official said it doesn't have to be that way. "If everybody engaged in safe sexual activities and didn't engage in illicit drug use, our disease burden would be cut in half," public health epidemiologist Michael Ruta said.
Ruta serves as epidemiologist for Columbiana, Carroll and Tuscarawas counties and prepared the 2008 End-Of-Year Infectious Disease Report for Columbiana County, a report he said shows that a majority of the diseases are easily preventable conditions just by people being more conscious about their health. Chlamydia and Hepatitis C infections accounted for 50 percent of the 212 valid disease reports received by the Columbiana County Health Department in 2008, coming in at number one and number two on the list.” Read more...
Test may have exposed Vets to deadly diseases
“Miami VA Healthcare System urges testing because of improperly sterilized tubes used in endoscopic procedures between 2004 and 2009. The Miami Veterans Affairs Healthcare System (MVAHS) has a warning for 3,260 veterans who were patients in endoscopic procedures during a 5-year period: Come in for free tests because there's a chance you were exposed to hepatitis B, hepatitis C or HIV.
MVAHS says those affected are veterans who had endoscopic procedures between May 2004 and March 12, 2009. Doctors say some of the tubing used was not disinfected according to the manufacturer's recommendations. A special Care Call center has been set up that is available 7 days a week, 24 hours a day.” Read more...
Drugs team give out cocaine straws
“Pieces of paper designed for snorting cocaine are being handed out to drug users across Kent, to stop them using rolled-up bank notes and spreading disease. The Maidstone-based Kent Drug and Alcohol Action Team, (KDAAT), responsible for the county’s drug treatment services, commissioned drugs charity KCA to make the notes.
The message on them reads: “Evidence suggests that the sharing of cocaine straws is a factor in the transmission of Hepatitis C. Reduce your chances of catching Hep C by using one of these single use notes instead of a bank note.”” Read more...
Nurse gets injury payout after 36 years
“A Swedish nurse who contracted Hepatitis C after coming into contact with an infected needle has had the cause of her sickness recognized by the authorities as a workplace injury after a 36 year wait. Agneta Bjurman had just qualified as a nurse when she inadvertently pricked herself with a syringe after carrying out tests on a man who was seriously ill.Shortly afterwards she began to feel unwell, but it took some time before she made the connection between the deterioration of her health and the incident with the needle.
Many years after the initial accident, in 1994, she was eventually diagnosed with Hepatitis C. But only now has the Swedish Social Insurance Agency (Försäkringskassan) agreed to accept that her illness was work-related, entitling her to some financial compensation.” Read more...
Vertex Hep C Drug Improves Cure Rate in Study
“Vertex Pharmaceuticals' experimental hepatitis C drug telaprevir is capable of significantly improving cure rates in the most difficult-to-treat patients, according to final results from a phase II study released Wednesday afternoon. The new data come from Vertex's PROVE 3 study, which enrolled 453 patients who had failed prior treatment with the current standard drug regimen for hepatitis C -- a 48-week course of long-acting interferon plus ribavirin. In the phase II study, these patients were randomized to receive either treatment with a combination of telaprevir plus the standard therapy or retreatment with the standard therapy alone.
In all, 51% of patients treated with a 24-week regimen that included 12 weeks of telaprevir reported undetectable levels of the hepatitis C virus six months after treatment. In hepatitis C parlance, that's known as a sustained virologic response, or SVR. Simply stated, these patients are considered cured of hepatitis C.By comparison, only 14% of the patients retreated with 48 weeks of standard therapy alone achieved an SVR, or cure, six months after treatment.” Read more...
Progress Reported Against Gene Involved in Hepatitis C
Finding could lead to new treatments for the disease, researchers say
“ Nearly 100 genes that support replication of the hepatitis C virus (HCV) in the human body have been identified by Massachusetts General Hospital researchers. They also found that blocking several of the genes suppressed replication of the virus.
"We may be a few years away from developing therapies based on these findings, but this study is a proof of principle that targeting host factors is a viable therapeutic strategy," Dr. Andrew Tai, of the hospital's gastrointestinal unit and lead researcher on the study, said in a hospital news release.” Read more...
and liver diseases: no joking matter
Maintaining a healthy digestive system is vital to your health and comfort.
But many people ignore the signs of digestive illness and fail to seek relief from their discomfort because they are embarrassed to discuss the symptoms or their own health histories…Another digestive disease, hepatitis C, requires discussions about potentially embarrassing aspects of a patient's personal history, including drug use and sexual activity.” Read more...
Tattoo secrets revealed: What Pamela Anderson wishes she had known http://www.examiner.com/x-322-Health-Care-Examiner~y2009m3d15-Tattoo-secrets-revealed-What-Barbie-doesnt-want-you-to-know
“Last time I mentioned Tattoo Barbie, the 50 year old toy that teaches girls how cool it will be when they can get a real tattoo of their own For now they can just practice. Well, tattoos are not child's play. And complications from tattoos are the dirty little secret no one wants to talk about. Sure most people want to think that they're sexy and a sign of creativity or a quirky personality. But like the Sneeches, when everyone has one, isn't it just, well, average?
The evidence has been mounting for the past decade that tattoos are not as safe as most believe-even when done in commercial tattoo establishments. Tattoo inks are classified as cosmetics, so they aren't regulated or approved by the Food and Drug Administration (FDA).The pigments and dyes used in tattoo inks aren't approved for injection under the skin. Long-term effects of these are unknown. They are also not regulated in most states. So, the risk those who wish to release their inner creativity is greater than most believe.”Read more...
It's time to consider needle exchange program
“Few images of drug use are more potent than that of the needle -- the needle in the shaky hand of a junkie searching the tracks on his arm or leg for a vein still able to receive one more injection; the needle hanging from the arm of an addict unconscious or dead from an overdose; the contaminated needle passing its deadly load of HIV or hepatitis to the next user and, through him, to his wife or lover and their unborn child.
A contaminated needle is an extremely efficient transmitter of a blood-borne disease. According to the Centers for Disease Control and Prevention, more than a third of AIDS cases in the United States have occurred among injecting drug users (IDUs), their sexual partners and their offspring. Hepatitis C, the most dangerous variant of that disease, is found in the blood of 70 to 90 percent of all adult IDUs.” Read more...
Vertex pays $100M for hep C-focused ViroChem
“Biotech Vertex Pharmaceuticals Inc. has wrapped its $100 million acquisition of ViroChem Pharma Inc., giving Vertex access to ViroChem’s hepatitis C virus drug research. ViroChem is a privately held company based in Laval, Quebec. Cambridge-based Vertex said that under the deal’s terms, Vertex will pay $100 million in cash and 10.7 million shares of its common stock. The shares issued for the merger will be available for resale when the registration statement is filed. Under terms of the deal, Vertex also owns worldwide rights to the ViroChem HCV drug development portfolio.
More specifically, ViroChem offers HCV Polymerase Inhibitors to Vertex. This will enable Vertex to create new combinations of specifically targeted antiviral therapies for hepatitis C in the treatment of HCV infection. Two of them are VCH-222 and VCH-759, which have demonstrated reductions in plasma HCV RNA when dosed as single agents and were well tolerated in early clinical studies. In the second half of the year, Vertex expects to begin clinical evaluation of new combination regimens of its HCV protease inhibitor telaprevir. The HCV protease inhibitor telaprevir is currently in Phase 3 clinical development.” Read more...
Army Believed to Have Infected 16 With Hepatitis
“Media outlets are breaking with news that Army officials are confirming that 16 patients have tested positive for hepatitis b and c. The Associated Press (AP) reported that the Army said the patients were likely exposed to the dangerous blood borne illnesses because of improper injection practices.
The 16 patients at the William Beaumont Army Medical Center were just some of the over 2,000 diabetics who might have been exposed to hepatitis b (HBV) and hepatitis c (HBC) and other blood borne illnesses, said the AP. It sees that multiple patients were administered injections from the same insulin pen, it noted. Smart Brief said that, according to the El Paso Times, each insulin pen is meant to be used by one individual, but the insulin pens were injected into multiples patients from August 2007 until the end of January. Journal Now said the program “systematically” injected multiple patients from the same pen; Lieutenant Colonel Sandy LaFon said that it remains unclear if the HBV and HBC infections originated from the shoddy injections or if there were previously undiagnosed infections.” Read more...
Schering say FDA expands hepatitis drug labels
“The Food and Drug Administration expanded the label for Schering-Plough Corp.'s hepatitis C drugs Pegintron and Rebetol, allowing the company to market the drugs for patients who have not recovered from the disease after previous treatment.
Schering-Plough said Wednesday that the FDA approved the drugs for the treatment chronic hepatitis C in patients with compensated liver disease. They were already approved for use in "treatment-naive" patients, or those who had never taken any drugs for the liver disease.” Read more...
Allmans shine their light on the Beacon
“ The Allman Brothers Band's 15 shows at the Beacon Theatre this month are billed as a 40th anniversary celebration. But their meaning goes deeper than that. The shows are dedicated to guitarist Duane Allman, the band's original leader and guiding force, who died in a 1971 motorcycle accident. And they mark the resumption of the band's annual Beacon stands after singer-keyboardist Gregg Allman's bout with hepatitis C forced the cancellation of last year's shows.
Gregg Allman has recovered. The band, a septet featuring two other original members (drummers Butch Trucks and Jaimoe), is back together. And even the Beacon is in great shape, following a seven-month, $16 million renovation. To help mark the anniversary and honor Duane Allman, a series of guest stars -- none officially confirmed ahead of time -- has been lined up to appear at various shows.” Read more...
UPDATE 3-Human Genome hepatitis C drug disappoints, shares crash
“ Human Genome Sciences' drug to treat chronic hepatitis C met the main goal in a late-stage trial, but failed to show numerically better efficacy compared to standard-of-care, raising questions about the drug's adoption and sending shares crashing to an all-time low. Analysts had expected the trial to meet its main goal of non-inferiority compared to Pegasys, but they had also said that the trial must show numerically better sustained virologic response (SVR) rates to convince the market of the drug's commercial viability.” Read more...
Hepatitis outbreaks caused by carelessness
“Sloppy clinical practices have caused 33 outbreaks of hepatitis B or hepatitis C infection in the past decade, the CDC reports after its first full-scale review of its own investigations (Ann Intern Med. 2009;150:33-39). As a result, more than 60,000 patients were told they needed diagnostic testing, 448 actually acquired the disease, and several lawsuits for malpractice have been filed.” Read more...
Proteomics prove accurate in identifying liver cancer
“As the incidence of liver cancer continues to grow-- fueled in large part, by rising rates of hepatitis C infections – so too does the need for tests to help diagnose the disease at an earlier stage.A study appearing in the January 15, 2008, issue of Clinical Cancer Research demonstrates that a novel mass-spectrometry based form of proteomic profiling is more accurate than traditional biomarkers in distinguishing liver cancer patients from patients with hepatitis C liver cirrhosis, particularly with regard to identifying patients with small, curable tumors. Led by researchers at Beth Israel Deaconess Medical Center (BIDMC), the study could help lead to earlier diagnostic methods – and subsequent treatments -- for liver cancer.” Read more...
Firefighter first to die in line of duty in Martin County fire-rescue's history
“ Hundreds gathered Monday to attend a funeral for a Martin County firefighter who died from an illness he contracted on the job. Fred Pierno Jr. died Wednesday at his Port St. Lucie home following a more than two-year battle with Hepatitis C virus, which he contracted while performing his duties with the Martin County Fire-Rescue Division.”
FTC clears ZymoGenetics-Bristol-Myers deal for hepatitis C drug development – Update
“ ZymoGenetics Inc. announced that its collaboration with Bristol-Myers Squibb Co. (BMY: News ) for hepatitis C compound PEG-Interferon lambda has been cleared by the United States Federal Trade Commission and Department of Justice clearance under provisions of the Hart-Scott-Rodino Antitrust Improvements Act.
PEG-Interferon lambda, (IL-29) is a novel type 3 interferon currently in Phase 1b development for Hepatitis C and is expected to be a more targeted therapy. Now that the collaboration agreement has become effective, following clearance, ZymoGenetics will receive payment of an $85.0 million licensing fee.’ Read more...
Hep C in HIVers may cause rapid liver disease
“Dr. Daniel Fierer spoke about HIV-hepatitis C coinfection at a forum in San Francisco last week. While HIV continues to garner the lion's share of attention regarding gay men's health, a second forum in as many months focused on the growing epidemic of hepatitis C among HIV-positive men who have sex with men – and presenters noted that rapid liver disease could be a result.” Read more...
Kerry urges probe of unsanitary conditions at VA
“Senator John F. Kerry this afternoon urged the inspector general at the Department of Veterans Affairs to investigate sanitation standards at VA hospitals, following reports this week that facilities in Florida and Tennessee rinsed, but did not disinfect equipment used in colonoscopies. As many as 9,000 patients may have had invasive procedures with contaminated equipment, potentially exposing them to infectious diseases including hepatitis.” Read more...
Hepatitis screening drive launched
“ISLAMABAD: The Directorate of Health Services of the Capital Development Authority (CDA) launched a screening campaign to detect Hepatitis B & C patients in staff of various hotels in the city. A press statement, issued on Saturday, said CDA health directorate would test staff of hotel, motels, restaurants, barber shops and salons for the disease. In this connection, 1,028 people had so far been screened, out of which 24 tested positive for Hepatitis B and 55 for Hepatitis C. This is an alarming situation, which needs to be tackled on war footing to stop the disease from becoming an epidemic. Dr Saeed Ahmed of CDA said Hepatitis B and C cases were increasing in the city rapidly. He appealed to general public to take precautionary measures against the disease.”
Global Challenges | Increase in heroin availability in Australia posing risk of HIV
“The Australian National Council on Drugs on Monday said that increased amounts of heroin entering the country from the Middle East and Asia could contribute to the spread of HIV among injection drug users, the Sydney Morning Herald reports. The council's Asia-Pacific Committee reported that heroin trafficking has increased and that border detections of the drug were the highest on record in 2006 and 2007.
According to committee chair Robert Ali, heroin use and overdose deaths in Australia have decreased since 2001, but overall global production has increased, creating new risks. He said that an increase in the availability of heroin could result in "recruitment of new drug users," adding, "It's recruiting a new group of users into injecting who think there is no HIV and don't know much about hepatitis C and just feeling that it's not risky. There's a perception that all of this has gone away, that it's no longer a problem." He added that there is "a real risk" of HIV and hepatitis C among IDUs.”Read more...
Using HIV as model, Anadys develops drug cocktail ingredient for hepatitis C
“HIV was transformed from a terminal illness into a chronic disease in wealthy countries in the late 1990s, once scientists learned to mix anti-viral drugs into a potent cocktail. That was supposed to hold the virus in check by attacking it from many different angles, keeping it from developing resistance to any one drug.
The same philosophy is now at work in hepatitis C, a chronic viral infection that causes liver damage.” Read more...
Doctor fears needle disease outbreak
SOMBA K'E/YELLOWKNIFE – “Intravenous crack cocaine, a huge factor in the HIV and hepatitis C outbreaks in Vancouver over the last few decades, is becoming a growing problem in Yellowknife, according to one emergency room doctor. Dr. David Pontin, a physician at Stanton Territorial Hospital, said he is beginning to see IV crack-related cases of hepatitis C in the ER.
In a letter addressed to the territorial government, Pontin wrote: "We have a situation here that is akin to kindling waiting for a flame. Our homeless population is highly addicted already and the introduction of IV crack use is the flame that will cause an explosion of HIV and hepatitis C." Crack cocaine in smoking form has given rise to hepatitis C and HIV problems in the past due to unsafe sex practised while on the drug. But melted down and injected, crack cocaine really kicks the spread of these diseases into high gear, he said.” Read more...
Sick, seeking answers
“Troy Anderson was already carrying the virus that was silently attacking his liver when he walked into a navy recruiting office on Duke Street in 1986. Twenty-three years later, he has only to look a few blocks from his Queen Street apartment to be reminded of his eagerness and ignorance that day.
But Anderson, now 43, doesn't have to look nearly as far for a reminder of the virus that was with him then and is with him now. With his hepatitis C in its advanced stages, he lives with wild swings in his weight, fatigue, near-constant pain and an expert opinion that he only has a few years left to live.
For 15 years, Anderson was sick with the disease without knowing it. Eight of those years were spent in the navy, where he received regular blood tests -- but he alleges incompetence or irresponsibility kept military doctors from diagnosing his illness.
It wasn't until 2000 that his hepatitis C was diagnosed by a civilian doctor. The physician suggested he had 10 years left to live.” Read more...
Hepatitis C group creates alert card (Japan)
“About 700 people with hepatitis C have created a card that contains information regarding their condition to alert medical staff in case of an emergency.
The card is aimed at notifying ambulance crews, doctors and other medical professionals that the owner of the card carries the hepatitis virus. It is hoped this will help medical staff avoid infection when the card owner is bleeding but cannot speak due to unforeseeable circumstances, such as being involved in a road accident.” Read more...
Have a heart, give a liver
“Susan Kingston, a Kemptville woman suffering from liver cirrhosis, sits in her home with loyal friend Tanner. Susan needs a new liver in order to live beyond the next couple of years and is seeking a donor. Susan Kingston is going to die. That is, unless she finds a new liver.
Without it, she could have anywhere from two to four years left. Kingston has put out a plea for help after her last visit to doctors at Toronto’s General Hospital made it clear that the chances of receiving a new liver in time to survive just isn’t likely to happen.
“They said, ‘You’re O-positive – there’s no chance we will be calling you,’” said Kingston in her home near Kemptville. “As the list is long, I would have to be bedridden in the hospital and airlifted to Toronto before I would be put higher on the list.”” Read more...
Music and coffee spread awareness
“When a friend asked her to spread awareness about Hepatitis C, Kelly Zirbes willingly accepted the task and got to work. Unknown to herself when she started, her devotion to the cause led her to become a successful advocate with an effective and contemporary style, speaking through music.
As the founder of the non-profit organization Hepatitis C Awareness Inc., Zirbes incorporates musical performances at her company’s events to entice others to learn about the virus.” Read more...
Liver cancer from hepatitis looms large in RI
“Indonesians are becoming increasingly more vulnerable to cancer of the liver, with more than 40,000 new cases detected each year, health experts warn.“Around 42,600 new cases of liver cancer occur every year in the country,” health expert Terawan Agus Putranto said Saturday during a seminar on cancer diagnosis and therapy in Jakarta.
“Most of the cases stem from hepatitis, which is a prevalent disease among Indonesians,” added the radiology specialist from Gading Pluit Hospital in North Jakarta.
He said careless use of needles and unmonitored blood transfusions had contributed significantly to the spread of hepatitis, which is transferable through blood, feces and sexual contact.” Read more...
Campaign addresses unsafe injection practices
“Nurses should know better. Syringes, IVs, and vials are never used more than once. It's basic nursing pratice taught in every nursing school program. But something has gone wrong. A spate of hepatitis B and C infections traced to unsafe injection practices at ambulatory care centers across the country has prompted the U.S. Centers for Disease Control and Prevention to join a new national education campaign emphasizing safe injection practices to nurses and other healthcare workers.” Read more...
Poor infection control caused kidney unit hep C infections
“ A failure to adequately test patients for hepatitis C and poor infection control led to the infection with the virus of nine hemodialysis patients in New York City, according to a report published in the Mar. 6 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.Renee Hallack, of New York State Department of Health, and colleagues report on an investigation into a private outpatient facility that treated between 70 and 100 patients at 30 dialysis stations each day. In May and July 2008, three cases of seroconversion from anti-hepatitis C virus negative to anti-hepatitis C virus positive were reported to the state health department and a subsequent investigation revealed that from 2001 to 2008 there were an additional six cases.’ Read more...
9m suffering from hepatitis C, Senate told (Pakistan)
“The Senate was informed on Friday that around 8.8 million people in Pakistan are suffering from deadly hepatitis C while another 5.6 million are affected by hepatitis B.
In written reply to a question, minister for health Aijaz Hussain Jhakrani said the figures have been compiled by a recent sero-prevalence study conducted by Pakistan Medical Research Council.“The quantum of hepatitis C and B are 4.9 percent and 2.5 percent respectively,” the minister added. He said the availability of diagnostic facilities and awareness campaigns have un-earthed the hidden burden of the disease.” Read more...
AcroMetrix announces the release of OptiQuant-S hepatitis C virus (HCV) panel
“ AcroMetrix, a leading manufacturer of molecular quality control standards and controls for clinical diagnostic and blood testing laboratories, announced today the release of the OptiQuant-S HCV RNA Quantification Panel. This new panel utilizes AcroMetrix's proprietary SynTura(TM) Technology and provides laboratories with a critical component to fully optimize the Hepatitis C molecular assays available in today's market.
Viral Hepatitis B and C now account for greater than 75% of all cases of liver disease around the world(1). HCV patients are routinely monitored for changes in the amount of virus (i.e. viral load) present in the patient when undergoing therapy for the disease. Physicians rely on the accuracy of the viral load test result provided by the laboratory to adjust and manage the drug regiment for the patient.” Read more...
Synthetic blood could be in circulation within 10 years
“For Bruce Norval, it is a breakthrough but one he is nevertheless wary of. He is one of more than 4,000 haemophilia sufferers who contracted Hepatitis C through contaminated blood transfusions in the 1970s and 1980s, so is cautiously optimistic about the research project conducted by Scottish scientists into the manufacture of synthetic blood from embryonic stem cells. “It will address a lot of problems,” he says, “but we need to be able to monitor its safety and learn from the mistakes of the past.”
The three-year clinical trial, which is being led by Professor Marc Turner, the director of the Scottish National Blood Transfusion Service, — the universal blood group which can be transfused into 98% of the population without being rejected — from the stem cells. If successful, scientists believe the blood will be disease-free and provide limitless supplies for transfusions, operations and emergency procedures, reducing the reliance on donors. By the end of the trial, they hope to be in a position to inject small amounts of the synthetic blood into volunteers to test its safety and viability, and within 10 years the process could be established on an industrial scale.”Read more...
Free hepatitis C screenings set (Illinois)
WOODSTOCK – In honor of Public Health Week, which will be April 6-12, the McHenry County Department of Health is offering free hepatitis C screenings to residents 18 and older. Screenings are available April 8, 9, 15, 16, 22 and 23 at the Annex B facility, 2200 N. Seminary Ave., Woodstock. Appointments are required…For information about the free hepatitis C screenings or to schedule an appointment, call the health department at 815-334-4500.” Read more...
Tattooing blamed for sharp rise in Hep C rates
“HEALTH WARNING: Health educators from the Hepatitis C Council of NSW Leon Fernandes (left), and Harpreet Kalsi. Young people who tattoo themselves with home kits purchased on the Internet risk contracting the potentially debilitating hepatitis C. Two hep C experts visiting the North Coast this week yesterday told The Northern Star the latest surge in the number of people with the disease were young people tattooing themselves and their friends. The kits can cost as little as $80, but a lack of hygiene meant potential infections; those infected would pay a higher price - possibly for the rest of their lives.” Read more...
Early Changes in Hepatitis C Virus (HCV) Levels in Response to Peginterferon and
Ribavirin Treatment in Patients with Chronic HCV Genotype 1 Infection.
Hoofnagle JH, Wahed AS, Brown Jr RS, et al. J Infect Dis. 2009 Apr 15;199(8):1112-1120 http://www.ncbi.nlm.nih.gov/pubmed/19284286?ordinalpos=38&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-alpha2b related severe neutropenia: A preliminary report on treatment, safety and efficacy. Koskinas J, Zacharakis G, Sidiropoulos J, et al. J Med Virol. 2009 Mar 24;81(5):848-852. [Epub ahead of print]
Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy. Yoshida EM, Sherman M, Bain VG, et al. Can J Gastroenterol. 2009 Mar;23(3):180-184.http://www.ncbi.nlm.nih.gov/pubmed/19319382?ordinalpos=4&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Is smoking a prognostic factor in patients with chronic hepatitis C? De Luca L, De Angelis C, Fagoonee S, et al. Minerva Gastroenterol Dietol. 2009 Jun;55(2):139-43. http://www.ncbi.nlm.nih.gov/pubmed/19305373?ordinalpos=12&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Palavecino M, Chun YS, Madoff DC, et al. Surgery. 2009 Apr;145(4):399-405.http://www.ncbi.nlm.nih.gov/pubmed/19303988?ordinalpos=14&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Autoantibodies in chronic hepatitis C virus infection and their association with disease profile. Williams MJ, Lawson A, Neal KR, et al. J Viral Hepat. 2009 Mar 3. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19302340?ordinalpos=18&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels. Iwasa M, Hara N, Miyachi H, et al. J Viral Hepat. 2009 Mar 3. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19302338?ordinalpos=20&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Smoking is associated with steatosis and severe fibrosis in chronic hepatitis C but not B. Tsochatzis E, Papatheodoridis GV, Manolakopoulos S, et al. Scand J Gastroenterol. 2009 Mar 18:1-8. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19296398?ordinalpos=25&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Treatment Outcomes With Pegylated Interferon and Ribavirin for Male Prisoners With Chronic Hepatitis C. Chew KW, Allen SA, Taylor LE, et al. J Clin Gastroenterol. 2009 Mar 17. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19295448?ordinalpos=26&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Clinical Implications of Alpha-fetoprotein in Chronic Hepatitis C. Tai WC, Hu TH, Wang JH, et al. J Formos Med Assoc. 2009 Mar;108(3):210-8 http://www.ncbi.nlm.nih.gov/pubmed/19293036?ordinalpos=28&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C. Neumann AU, Bain VG, Yoshida EM, et al. Liver Int. 2009 Mar 11. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19291180?ordinalpos=30&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients. Ebner N, Wanner C, Winklbaur B, et al. Addict Biol. 2009 Apr;14(2):227-37. http://www.ncbi.nlm.nih.gov/pubmed/19291011?ordinalpos=31&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 16 cases. Dufour JF, Pradat P, Ruivard M, et al. Eur J Gastroenterol Hepatol. 2009 Mar;21(3):245-53. http://www.ncbi.nlm.nih.gov/pubmed/19279468?ordinalpos=43&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Treatment of hepatitis C in hemodialysis patients using pegylated interferon
alpha-2a in Turkey. Kose S, Gurkan A, Akman F, Kelesoglu M, Uner U. J Gastroenterol. 2009 Mar 11. [Epub ahead of print]
Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices. Nomura H, Miyagi Y, Tanimoto H, et al. J Gastroenterol. 2009 Mar 10. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19277449?ordinalpos=46&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Rituximab in cryoglobulinemic peripheral neuropathy. Cavallo R, Roccatello D, Menegatti E, et al. J Neurol. 2009 Mar 5. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19263187?ordinalpos=64&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load. Arase Y, Suzuki F, Akuta N, et al. Intern Med. 2009;48(5):253-8. Epub 2009 Mar 2. http://www.ncbi.nlm.nih.gov/pubmed/19252344?ordinalpos=71&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Incidence of prolonged length of stay after orthotopic liver transplantation and its influence on outcomes. Smith JO, Shiffman ML, Behnke M, et al. Liver Transpl. 2009 Mar;15(3):273-9. http://www.ncbi.nlm.nih.gov/pubmed/19243008?ordinalpos=73&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. Rodrigue JR, Balistreri W, Haber B, et al. J Pediatr Gastroenterol Nutr. 2009 Mar;48(3):341-7 http://www.ncbi.nlm.nih.gov/pubmed/19242286?ordinalpos=74&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy.Mori N, Imamura M, Kawakami Y, et al. J Med Virol. 2009 Apr;81(4):640-9. http://www.ncbi.nlm.nih.gov/pubmed/19235866?ordinalpos=76&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy.
Hayashi K, Katano Y, Honda T, et al. J Med Virol. 2009 Mar;81(3):459-66. http://www.ncbi.nlm.nih.gov/pubmed/19152412?ordinalpos=93&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. Akuta N, Suzuki F, Hirakawa M, et al. J Med Virol. 2009 Mar;81(3):452-8. http://www.ncbi.nlm.nih.gov/pubmed/19152407?ordinalpos=94&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Long-term follow-up of patients with hepatitis C with a normal alanine aminotransferase. Kumada T, Toyoda H, Kiriyama S, et al. J Med Virol. 2009 Mar;81(3):446-51. http://www.ncbi.nlm.nih.gov/pubmed/19152400?ordinalpos=96&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Arase Y, Suzuki F, Suzuki Y, et al. Hepatology. 2009 Mar;49(3):739-44. http://www.ncbi.nlm.nih.gov/pubmed/19127513?ordinalpos=98&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Severe hepatocellular injury with apoptosis induced by a hepatitis C polymerase inhibitor. Feldstein A, Kleiner D, Kravetz D, Buck M. J Clin Gastroenterol. 2009 Apr;43(4):374-81.
Is the rapid virologic response a positive predictive factor of sustained virologic response in all pretreatment status genotype 1 hepatitis c patients treated with peginterferon-alpha2b and ribavirin? de Segadas-Soares JA, Villela-Nogueira CA, Perez RM, et al. J Clin Gastroenterol. 2009 Apr;43(4):362-6. http://www.ncbi.nlm.nih.gov/pubmed/19077732?ordinalpos=103&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. George SL, Bacon BR, Brunt EM, et al. Hepatology. 2009 Mar;49(3):729-38. http://www.ncbi.nlm.nih.gov/pubmed/19072828?ordinalpos=104&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Narcotic analgesics and progression of fibrosis in patients with chronic hepatitis C. Vallejos C, Bordin-Wosk T, Pockros L, Feng A, Pockros P. J Clin Gastroenterol. 2009 Apr;43(4):357-61.
Early gene expression profiles of patients with chronic hepatitis C treated with
pegylated interferon-alfa and ribavirin. Younossi ZM, Baranova A, Afendy A, et al. Hepatology. 2009 Mar;49(3):763-74. http://www.ncbi.nlm.nih.gov/pubmed/19140155?ordinalpos=97&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication. Vaillancourt FH, Pilote L, Cartier M, et al. Virology. 2009 Mar 20. [Epub ahead of print]
Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-dependent RNA Polymerase. Shi ST, Herlihy KJ, Graham JP, et al. Antimicrob Agents Chemother. 2009 Mar 23. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/19307358?ordinalpos=9&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Chronic hepatitis C in the advanced adult and elderly subjects. Gattoni A, Parlato A, Vangieri B, Bresciani M, Petraccaro M. Minerva Gastroenterol Dietol. 2009 Jun;55(2):145-57.
Early viraemia clearance during antiviral therapy of chronic hepatitis C improves dendritic cell functions. Pachiadakis I, Chokshi S, Cooksley H, et al. Clin Immunol. 2009 Mar 19. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19303818?ordinalpos=15&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Selection Pressure from Neutralizing Antibodies Drives Sequence Evolution during Acute Infection with Hepatitis C Virus. Dowd KA, Netski DM, Wang XH, Cox AL, Ray SC. Gastroenterology. 2009 Mar 17. [Epub ahead of print
Inhibition of intracellular hepatitis C virus replication by nelfinavir and synergistic effect with interferon-alpha. Toma S, Yamashiro T, Arakaki S, et al. J Viral Hepat. 2009 Mar 3. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19302339?ordinalpos=19&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Low interleukin-10 production by monocytes of patients with a self-limiting hepatitis C virus infection. Martin-Blondel G, Gales A, Bernad J, et al. J Viral Hepat. 2009 Mar 11. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19302337?ordinalpos=21&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Residues in a Highly Conserved Claudin-1 Motif Are Required for Hepatitis C Virus
Entry and Mediate the Formation of Cell-Cell Contacts. Cukierman L, Meertens L, Bertaux C, Kajumo F, Dragic T. J Virol. 2009 Mar 18. [Epub ahead of print]
Hepatitis C virus and ethanol alter antigen presentation in liver cells. Osna NA. World J Gastroenterol. 2009 Mar 14;15(10):1201-8.
The effect of obesity on intrahepatic cytokine and chemokine expression in chronic hepatitis C infection. Palmer C, Corpuz T, Guirguis M, et al. Gut. 2009 Mar 15. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19289381?ordinalpos=32&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
The pathway of hepatitis C virus mRNA recruitment to the human ribosome. Fraser CS, Hershey JW, Doudna JA. Nat Struct Mol Biol. 2009 Mar 15. [Epub ahead of print]
Infection of B cells with hepatitis C virus for the development of lymphoproliferative disorders in patients with chronic hepatitis C. Inokuchi M, Ito T, Uchikoshi M, Shimozuma Y, et al. J Med Virol. 2009 Apr;81(4):619-27. http://www.ncbi.nlm.nih.gov/pubmed/19235854?ordinalpos=78&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Risk factors for HCV infection. Focus on ethnic and cultural characteristics.
Pellicano R, De Angelis C, De Luca L, et al. Minerva Gastroenterol Dietol. 2009 Jun;55(2):159-62.
Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. Collin F, Duval X, Le Moing V, et al. AIDS. 2009 Mar 18. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/19300202?ordinalpos=22&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Saquinavir exposure in HIV-infected patients with chronic viral hepatitis. Moltó J, Llibre JM, Ribera E, et al. J Antimicrob Chemother. 2009 Mar 11. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19279052?ordinalpos=44&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial. Van den Eynde E, Crespo M, Esteban JI, et al. Clin Infect Dis. 2009 Apr 15;48(8):1152-9. http://www.ncbi.nlm.nih.gov/pubmed/19275492?ordinalpos=49&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals. Vogel M, Bertram N, Wasmuth JC, et al. J Antimicrob Chemother. 2009 Mar 6. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19270314?ordinalpos=53&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Longitudinal Trends in Hazardous Alcohol Consumption Among Women With Human
Immunodeficiency Virus Infection, 1995-2006. Cook RL, Zhu F, Belnap BH, et al. Am J Epidemiol. 2009 Mar 6. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19270052?ordinalpos=54&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Kirk GD, Astemborski J, Mehta SH, et al. Clin Infect Dis. 2009 Apr 1;48(7):963-72. http://www.ncbi.nlm.nih.gov/pubmed/19236273?ordinalpos=75&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Hepatitis C, human immunodeficiency virus and metabolic syndrome: interactions.
Kotler DP. Liver Int. 2009 Mar;29 Suppl 2:38-46.
Nonalcoholic Fatty Liver Disease Among HIV-Infected Persons. Crum-Cianflone N, Dilay A, Collins G, et al. J Acquir Immune Defic Syndr. 2009 Apr;50(5):464-473.http://www.ncbi.nlm.nih.gov/pubmed/19225402?ordinalpos=86&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Characteristics and treatment outcomes among HIV-infected individuals in the
Australian Trial in Acute Hepatitis C. Matthews GV, Hellard M, Haber P, et al. Clin Infect Dis. 2009 Mar 1;48(5):650-8.http://www.ncbi.nlm.nih.gov/pubmed/19191653?ordinalpos=90&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Isoflavone consumption and subsequent risk of hepatocellular carcinoma in a population-based prospective cohort of Japanese men and women. Kurahashi N, Inoue M, Iwasaki M, et al. Int J Cancer. 2009 Apr 1;124(7):1644-9. http://www.ncbi.nlm.nih.gov/pubmed/19089922?ordinalpos=101&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Perinatal transmission of hepatitis C virus infection. Indolfi G, Resti M. J Med Virol. 2009 Mar 24;81(5):836-843. [Epub ahead of print]
Lack of association between genotypes and subtypes of HCV and occurrence of hepatocellular carcinoma in Egypt. Ryu SH, Fan X, Xu Y, Elbaz T, et al. J Med Virol. 2009 Mar 24;81(5):844-847. [Epub ahead of print]
Evaluation of immigration status, race and language barriers on chronic hepatitis
C virus infection management and treatment outcomes.Giordano C, Druyts EF, Garber G, Cooper C. Eur J Gastroenterol Hepatol. 2009 Mar 21. [Epub ahead of print]
Recurrence of hepatitis C virus genotype-4 infection following orthotopic liver
transplantation: natural history and predictors of outcome. Mudawi H, Helmy A, Kamel Y, et al. Ann Saudi Med. 2009 Mar-Apr;29(2):91-7.
FibroScan and ultrasonography in the prediction of hepatic fibrosis in patients
with chronic viral hepatitis. Wang JH, Changchien CS, Hung CH, et al. J Gastroenterol. 2009 Mar 25. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19308312?ordinalpos=7&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Improvement in Dissolution of Liver Fibrosis in an Animal Model by Tetrathiomolybdate. Hou G, Dick R, Brewer GJ. Exp Biol Med (Maywood). 2009 Mar 23. [Epub ahead of print]
Liver cancer mortality among male prison inmates in Texas, 1992-2003. Harzke AJ, Baillargeon JG, Goodman KJ, Pruitt SL. Prev Med. 2009 Mar 13. [Epub ahead of print]
Treatment strategies for a patient with rheumatoid arthritis and hepatitis C.
Giannitti C, Bellisai F, Ferri C, Galeazzi M. Expert Opin Pharmacother. 2009 Mar;10(4):579-87.
Estimating hepatitis C infection acquired in England, 1986-2000. Balogun MA, Vyse AJ, Hesketh LM, et al. Epidemiol Infect. 2009 Mar 10:1-6. [Epub ahead of print]
Antibody to hepatitis B core antigen as a screening test for occult hepatitis B
virus infection in Egyptian chronic hepatitis C patients. El-Sherif A, Abou-Shady M, Abou-Zeid H, et al. J Gastroenterol. 2009 Mar 7. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/19271112?ordinalpos=52&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Does cirrhosis affect quality of life in hepatitis C virus-infected patients? Hsu PC, Krajden M, Yoshida EM, et al. Liver Int. 2009 Mar;29(3):449-58. http://www.ncbi.nlm.nih.gov/pubmed/19267865?ordinalpos=57&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Hepatitis C virus transmission at an outpatient hemodialysis unit--New York,
2001-2008. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2009 Mar 6;58(8):189-94.
Patterns of viraemia in haemodialysis patients with hepatitis C. Dzekova-Vidimliski P, Asani A, Selim G, et al. Prilozi. 2009 Dec;29(2):201-12. http://www.ncbi.nlm.nih.gov/pubmed/19259047?ordinalpos=66&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy. Chehadeh W, Al-Nakib W. J Med Virol. 2009 Apr;81(4):610-8.
Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Negro F, Sanyal AJ. Liver Int. 2009 Mar;29 Suppl 2:26-37.
Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Serfaty L, Capeau J. Liver Int. 2009 Mar;29 Suppl 2:13-25.
Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus:
impact on disease progression and treatment response. Younossi ZM, McCullough AJ. Liver Int. 2009 Mar;29 Suppl 2:3-12.
Lay management of chronic disease: a qualitative study of living with hepatitis C
infection. Stoller EP, Webster NJ, Blixen CE, et al. Am J Health Behav. 2009 Jul-Aug;33(4):376-90. http://www.ncbi.nlm.nih.gov/pubmed/19182983?ordinalpos=91&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum
A new HCV genotype 6 subtype designated 6v was confirmed with three complete
genome sequences. Wang Y, Xia X, Li C, et al.. J Clin Virol. 2009 Mar;44(3):195-9.
Analysis of gene transcription in sera during chronic hepatitis C infection. Carpentier A, Conti F, Carrière M, et al. J Med Virol. 2009 Mar;81(3):473-80. http://www.ncbi.nlm.nih.gov/pubmed/19152403?ordinalpos=95&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVDocSum